AbbVie’s Final Phase 3 MIRASOL Data Confirms 32% Reduced Risk of Death with ELAHERE in Platinum-Resistant Ovarian Cancer

Final data analysis from Phase 3 MIRASOL trial after 30.5-month median follow-up demonstrated 32% reduction in risk of death with E...

March 17, 2025 | Monday | News
Gradalis Publishes Study Validating Clonal Tumor Mutation Burden as Key to Immunotherapy Targeting

Optimal therapeutic targeting of cancer involves clonal signals which are expressed within all cancer cells Gradalis applies a novel clinically releva...

March 14, 2025 | Friday | Reports
Celldex Reports Positive Phase 2 Results for Barzolvolimab in Chronic Urticaria

Celldex Therapeutics, Inc. announced  positive data on measurements of disease control and quality of life from the Company’s Phase 2 barzolvoli...

March 03, 2025 | Monday | News
Roche Group Unveils Promising Results from NIH-Sponsored OUtMATCH Study, Highlighting Xolair® as a Leading Treatment for Food Allergies

Roche Group announced new positive data from Stage 2 and Stage 3 of the National Institutes of Health (NIH)-sponsored Phase III OUtMATCH study, which provi...

March 03, 2025 | Monday | News
Philadelphia’s Biotech Powerhouse: The City Fueling the United States of America’s Next Medical Breakthroughs

Philadelphia has long been known as a hub for history, education, and culture. But in recent years, the city has also solidified itself as a powerhouse i...

February 20, 2025 | Thursday | Reports
Merck (Known as MSD Outside the U.S. & Canada) Reports Strong 2024 Growth – CEO Robert M. Davis Highlights KEYTRUDA, WINREVAIR, and Pipeline Momentum

Fourth-Quarter Worldwide Sales Were $15.6 Billion, an Increase of 7% From Fourth Quarter 2023; Excluding the Impact of Foreign Exchange, Growth W...

February 04, 2025 | Tuesday | Company results
Albert Bourla Leads Pfizer to $63.6B Triumph in 2024 – Record Growth, Bold Strategy, and a Sharpened Vision for 2025!

Pfizer Inc. reported robust financial results for the full year 2024, achieving total revenues of $63.6 billion, reflecting a 7% year-over-year operation...

February 04, 2025 | Tuesday | Company results
Pfizer Announces Positive Phase 3 CREST Trial Results for Sasanlimab in High-Risk Non-Muscle Invasive Bladder Cancer

Clinically meaningful and statistically significant results are the first pivotal Phase 3 data for sasanlimab, a subcutaneously administered PD-1...

January 13, 2025 | Monday | News
Bayer Submits Supplemental New Drug Application for KERENDIA® (Finerenone) to Treat Heart Failure with Preserved or Mildly Reduced Ejection Fraction

Bayer announced the submission of a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) for KERENDIA® (finerenone...

January 13, 2025 | Monday | News
Grifols Submits Biologics License Application for New Fibrinogen Treatment to FDA

Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, announced it has submitted a B...

January 10, 2025 | Friday | News
Positive SIRONA Study Results Highlight Sirolimus-Coated Balloons as Effective Alternative to Paclitaxel for PAD Treatment

Concept Medical Inc., a global leader in innovative drug delivery technologies, is proud to report positive results from the SIRONA (Head-to-Head...

January 08, 2025 | Wednesday | News
Jacobio Pharma's KRAS G12C Inhibitor Glecirasib Data Published in Nature Medicine, Showcasing Impressive Efficacy in NSCLC

Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets announced that the data from a registrational clinical trial of...

January 07, 2025 | Tuesday | News
Korean Researchers Pioneer Breakthrough Technique to Transform Fibroblasts into Functional Heart Cells

Korean scientists discover a groundbreaking method to transform ordinary fibroblasts into mature cardiomyocytes Researchers at Korea University have achie...

December 27, 2024 | Friday | News
HKBU and Shanghai Sixth People's Hospital Pioneer Breakthrough Treatment for Rare Bone Disease XLH

A research led by Hong Kong Baptist University (HKBU) and the Shanghai Sixth People's Hospital Affiliated to School of Medicine at Shanghai Jiao ...

December 23, 2024 | Monday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close